Browse studies

Find your next paid study

5 recruiting studies matching your filters

A First-in-human Phase I, Open-label, Multicentre, Dose Escalation Trial of BI 3819026 in Combination With Ezabenlimab in Patients With Unresectable Advanced or Metastatic Solid Cancers to Determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE)

This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tol…

Advanced Solid CancerMetastatic Solid Cancer

Estimated

~$10 – $7,500

Boehringer IngelheimNCT07607678

Phase 2

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Solid Cancer

Estimated

~$10 – $7,500

Daiichi SankyoNCT06161025

Phase 1

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effe…

Advanced Solid Cancers

Estimated

~$10 – $7,500

BioNTech SENCT07186842

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (C…

Lung Cancer (Diagnosis)OsteochondromaSpitz Nevus+14 more

Estimated

~$10 – $1,125

Dana-Farber Cancer InstituteNCT07675967

Observational

xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed/ Refractory Cancers

Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision …

CancerNeoplamsRefractory+5 more

Estimated

~$10 – $8,750

First Ascent Biomedical Inc.NCT07167381